2341568
Cooperative Agreement
Overview
Grant Description
Sbir Phase II: Novel Progesterone Biosensor for Monitoring Fertility Health -this small business innovation research (SBIR) phase II project provides more 7.7 million women in the U.S. struggling with infertility a quantitative and affordable way to assess their ovulatory health. This progesterone biosensor is the first outcome of a platform technology built to improve at-home blood diagnostics and telehealth implementation.
This project will produce a novel class of inexpensive, real-time, and point-of-care biosensors. The commercialization of this product may also increase public engagement and comfort with biosensors and at-home diagnostics. In concert with informational videos, website pages, and workshops the commercialization of this product will improve scientific literacy.
Finally, the affordability of this product may help narrow the disparity of access to fertility technology allowing for more socioeconomically disadvantaged and underserved populations equal opportunity to assess their fertility. This small business innovation research (SBIR) phase II project is developing a novel class of biosensors for progesterone.
The technical hurdles to be addressed are to first translate optical transduction technology onto low-cost paper strips, then to determine the efficacy of the biosensors as paper test strips. The team will then develop a low-cost and portable measurement device which reads the paper lateral flow strips.
The anticipated technical results are a lateral-flow strip device which can measure progesterone from clinical blood samples of women who have never been pregnant, women with polycystic ovary syndrome (PCOS), pre-menopausal women, and post-menopausal women down to levels which indicate successful ovulation. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
- Subawards are not planned for this award.
This project will produce a novel class of inexpensive, real-time, and point-of-care biosensors. The commercialization of this product may also increase public engagement and comfort with biosensors and at-home diagnostics. In concert with informational videos, website pages, and workshops the commercialization of this product will improve scientific literacy.
Finally, the affordability of this product may help narrow the disparity of access to fertility technology allowing for more socioeconomically disadvantaged and underserved populations equal opportunity to assess their fertility. This small business innovation research (SBIR) phase II project is developing a novel class of biosensors for progesterone.
The technical hurdles to be addressed are to first translate optical transduction technology onto low-cost paper strips, then to determine the efficacy of the biosensors as paper test strips. The team will then develop a low-cost and portable measurement device which reads the paper lateral flow strips.
The anticipated technical results are a lateral-flow strip device which can measure progesterone from clinical blood samples of women who have never been pregnant, women with polycystic ovary syndrome (PCOS), pre-menopausal women, and post-menopausal women down to levels which indicate successful ovulation. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
- Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH PHASE II (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE II", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23516
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Cambridge,
Massachusetts
02139-4980
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 12/31/25 to 06/30/26 and the total obligations have increased 20% from $1,000,000 to $1,199,999.
Biosens8 was awarded
Cooperative Agreement 2341568
worth $1,199,999
from National Science Foundation in January 2024 with work to be completed primarily in Cambridge Massachusetts United States.
The grant
has a duration of 2 years 5 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Cooperative Agreement was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase II Programs (SBIR/STTR Phase II).
SBIR Details
Research Type
SBIR Phase II
Title
SBIR Phase II: Novel progesterone biosensor for monitoring fertility health
Abstract
This Small Business Innovation Research (SBIR) Phase II project provides more 7.7 million women in the U.S. struggling with infertility a quantitative and affordable way to assess their ovulatory health. This progesterone biosensor is the first outcome of a platform technology built to improve at-home blood diagnostics and telehealth implementation. This project will produce a novel class of inexpensive, real-time, and point-of-care biosensors. The commercialization of this product may also increase public engagement and comfort with biosensors and at-home diagnostics. In concert with informational videos, website pages, and workshops the commercialization of this product will improve scientific literacy. Finally, the affordability of this product may help narrow the disparity of access to fertility technology allowing for more socioeconomically disadvantaged and underserved populations equal opportunity to assess their fertility.
This Small Business Innovation Research (SBIR) Phase II project is developing a novel class of biosensors for progesterone. The technical hurdles to be addressed are to first translate optical transduction technology onto low-cost paper strips, then to determine the efficacy of the biosensors as paper test strips. The team will then develop a low-cost and portable measurement device which reads the paper lateral flow strips. The anticipated technical results are a lateral-flow strip device which can measure progesterone from clinical blood samples of women who have never been pregnant, women with Polycystic Ovary Syndrome (PCOS), pre-menopausal women, and post-menopausal women down to levels which indicate successful ovulation.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 23-516
Status
(Ongoing)
Last Modified 9/18/25
Period of Performance
1/15/24
Start Date
6/30/26
End Date
Funding Split
$1.2M
Federal Obligation
$0.0
Non-Federal Obligation
$1.2M
Total Obligated
Activity Timeline
Transaction History
Modifications to 2341568
Additional Detail
Award ID FAIN
2341568
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
V2HHGDEF15B1
Awardee CAGE
8V2H3
Performance District
MA-07
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Modified: 9/18/25